GLP-1 Agonist Peptides against Type 2 Diabetes Are Promising Targets for Patients with Poor Hb1Ac Control Type 2 diabetes is a major risk factor for cardiovascular disease related morbidity and ...

The incretin hormone glucagon-like peptide 1 (GLP-1), as well as GLP-1 analogues that are now being used for the treatment of patients with type 2 diabetes, potently suppresses α-cell secretion.

Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain.

Novel Glucagon like peptide-1 (GLP-1) drugs designed for type II diabetes. Hefei Institutes of Physical Science, Chinese Academy of Sciences . Journal Pharmaceuticals DOI 10.3390/ph15060740.

The glucagon-like peptide 1 (GLP-1) agonist market size was valued at USD 10.8 Billion in 2023 and is expected to reach a market size of USD 21.2 Billion by 2032 at a CAGR of 7.8%.Fort Collins, ...

Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors Mon Nov 28, 2011 1:02am EST Addex Pharmaceuticals / Addex ...

Glucagon-like peptide-1 receptor agonists related to adolescent weight loss, study suggests Date: February 4, 2013 Source: American Medical Association (AMA) ...

Glucagon-like-peptide-1 (GLP1) analogs may induce thyroid or pancreatic diseases in animals, raising questions about their use in diabetic patients. There is, however, controversy regarding ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results.&ldquo ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...